Barclays Begins Coverage on MiniMed Group (NASDAQ:MMED)

Equities research analysts at Barclays initiated coverage on shares of MiniMed Group (NASDAQ:MMED) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage set an “overweight” rating and a $26.00 price target on the stock. Barclays‘s price target suggests a potential upside of 85.58% from the stock’s current price.

A number of other research firms also recently issued reports on MMED. The Goldman Sachs Group started coverage on shares of MiniMed Group in a report on Tuesday. They set a “buy” rating and a $24.00 price objective for the company. Bank of America assumed coverage on MiniMed Group in a research report on Tuesday. They set a “buy” rating and a $27.00 price target on the stock. Citigroup initiated coverage on MiniMed Group in a research note on Tuesday. They set a “buy” rating and a $23.00 price target for the company. Mizuho assumed coverage on MiniMed Group in a research report on Tuesday. They set an “outperform” rating and a $21.00 price objective on the stock. Finally, Wall Street Zen raised MiniMed Group to a “hold” rating in a report on Saturday, March 14th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.45.

MiniMed Group Stock Down 3.2%

MMED stock opened at $14.01 on Wednesday. MiniMed Group has a one year low of $13.52 and a one year high of $20.48.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
• Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
• Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
• Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
• Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
• Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
• Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
• Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
• Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
• Neutral Sentiment: Mizuho began coverage on MMED. Article Title
• Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
• Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.